Tatva Chintan Pharma Chem Limited (BOM:543321)
India · Delayed Price · Currency is INR 1,616.00
-21.75 (-1.33%)
At close: Aug 21, 2026
Tatva Chintan Pharma Chem Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 37,811 | 24,618 | 15,840 | 25,231 | 36,995 | 51,166 | |
Market Cap Growth | 46.33% | 55.42% | -37.22% | -31.80% | -27.70% | - |
Enterprise Value | 38,927 | 25,276 | 15,844 | 24,403 | 37,505 | 50,113 |
Last Close Price | 1616.00 | 1050.90 | 678.28 | 1076.27 | 1659.80 | 2296.05 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 73.58 | 58.54 | 277.26 | 83.12 | 81.33 | 53.37 |
PS Ratio | 6.80 | 4.87 | 4.14 | 6.41 | 8.73 | 11.80 |
PB Ratio | 4.84 | 3.15 | 2.14 | 3.42 | 7.19 | 10.82 |
P/TBV Ratio | 4.88 | 3.18 | 2.16 | 3.44 | 7.19 | 10.82 |
P/OCF Ratio | 120.08 | 78.18 | 64.21 | 25.73 | 133.16 | 252.92 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 7.00 | 5.00 | 4.14 | 6.20 | 8.85 | 11.56 |
EV/EBITDA Ratio | 35.68 | 27.13 | 47.71 | 35.40 | 55.46 | 46.26 |
EV/EBIT Ratio | 55.86 | 44.89 | 237.11 | 55.74 | 64.15 | 49.87 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.15 | 0.15 | 0.05 | 0.02 | 0.33 | 0.25 |
Debt / EBITDA Ratio | 1.10 | 1.29 | 1.09 | 0.21 | 2.51 | 1.10 |
Net Debt / Equity Ratio | 0.14 | 0.14 | 0.03 | -0.04 | 0.25 | 0.12 |
Net Debt / EBITDA Ratio | 1.02 | 1.20 | 0.74 | -0.45 | 1.91 | 0.52 |
Net Debt / FCF Ratio | - | -1.36 | -0.48 | 1.03 | -0.74 | -0.81 |
Asset Turnover | - | 0.55 | 0.46 | 0.50 | 0.60 | 0.89 |
Inventory Turnover | - | 1.36 | 1.44 | 1.16 | 1.40 | 1.67 |
Quick Ratio | - | 0.60 | 1.07 | 1.48 | 0.54 | 0.73 |
Current Ratio | - | 1.64 | 2.76 | 3.74 | 1.31 | 2.55 |
Return on Equity (ROE) | - | 5.53% | 0.77% | 4.85% | 9.21% | 30.00% |
Return on Assets (ROA) | - | 3.82% | 0.51% | 3.47% | 5.16% | 12.91% |
Return on Invested Capital (ROIC) | 5.81% | 5.01% | 0.69% | 4.52% | 9.97% | 23.72% |
Return on Capital Employed (ROCE) | - | 7.10% | 0.90% | 5.90% | 11.20% | 20.60% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 1.36% | 1.71% | 0.36% | 1.20% | 1.23% | 1.87% |
FCF Yield | -2.18% | -3.34% | -3.26% | -1.21% | -4.74% | -1.35% |
Dividend Yield | 0.06% | 0.19% | 0.15% | 0.19% | 0.12% | 0.09% |
Payout Ratio | - | 5.56% | 81.88% | 15.41% | 9.75% | - |
Buyback Yield / Dilution | 0.19% | 0.01% | -2.20% | -3.27% | -3.10% | -7.03% |
Total Shareholder Return | 0.25% | 0.20% | -2.05% | -3.08% | -2.98% | -6.94% |